http://venturebeat.com/2007/07/30/talecris-biotherapeutics-files-for-1b-ipo-is-it-the-end-of-the-private-equity-boom/ News About Tech, Money and Innovation Thu, 26 Nov 2009 01:33:32 +0000 http://wordpress.org/?v=2.8.5 hourly 1 http://venturebeat.com/2007/07/30/talecris-biotherapeutics-files-for-1b-ipo-is-it-the-end-of-the-private-equity-boom/comment-page-1/#comment-606258 VentureBeat » Life sciences briefing: Tuesday, Oct. 30, 2007 Wed, 31 Oct 2007 10:56:20 +0000 http://venturebeat.com/2007/07/30/talecris-biotherapeutics-files-for-1b-ipo-is-it-the-end-of-the-private-equity-boom/#comment-606258 [...] since they offer lower risk even at the cost of slower growth. Perhaps there’s hope for Talecris Biotherapeutics after [...] [...] since they offer lower risk even at the cost of slower growth. Perhaps there’s hope for Talecris Biotherapeutics after [...]

]]> http://venturebeat.com/2007/07/30/talecris-biotherapeutics-files-for-1b-ipo-is-it-the-end-of-the-private-equity-boom/comment-page-1/#comment-606272 VentureBeat » Life sciences briefing: Tuesday, Oct. 30, 2007 Wed, 31 Oct 2007 10:56:20 +0000 http://venturebeat.com/2007/07/30/talecris-biotherapeutics-files-for-1b-ipo-is-it-the-end-of-the-private-equity-boom/#comment-606272 [...] since they offer lower risk even at the cost of slower growth. Perhaps there’s hope for Talecris Biotherapeutics after [...] [...] since they offer lower risk even at the cost of slower growth. Perhaps there’s hope for Talecris Biotherapeutics after [...]

]]> http://venturebeat.com/2007/07/30/talecris-biotherapeutics-files-for-1b-ipo-is-it-the-end-of-the-private-equity-boom/comment-page-1/#comment-585076 VentureBeat » Life sciences briefing: Thursday, Oct. 18, 2007 Thu, 18 Oct 2007 18:14:29 +0000 http://venturebeat.com/2007/07/30/talecris-biotherapeutics-files-for-1b-ipo-is-it-the-end-of-the-private-equity-boom/#comment-585076 [...] The latest IPO terms represent a significant step up from Nanotech’s initial plan to raise $100 million in the offering, which we wrote about here (seventh item). Either way, it’s still a fairly princely sum, particularly given that only two U.S. pharma/biotechs — the specialty pharmas Jazz Pharmaceuticals (covered here) and Eurand — have managed to pull in more than $100 million with IPOs this year. Of course, none of these companies holds a candle to Talecris Biotherapeutics, which apparently still thinks it can raise $1 billion in an initial offering. [...] [...] The latest IPO terms represent a significant step up from Nanotech’s initial plan to raise $100 million in the offering, which we wrote about here (seventh item). Either way, it’s still a fairly princely sum, particularly given that only two U.S. pharma/biotechs — the specialty pharmas Jazz Pharmaceuticals (covered here) and Eurand — have managed to pull in more than $100 million with IPOs this year. Of course, none of these companies holds a candle to Talecris Biotherapeutics, which apparently still thinks it can raise $1 billion in an initial offering. [...]

]]> http://venturebeat.com/2007/07/30/talecris-biotherapeutics-files-for-1b-ipo-is-it-the-end-of-the-private-equity-boom/comment-page-1/#comment-508244 VentureBeat » California’s stem-cell management disarray Tue, 04 Sep 2007 01:59:16 +0000 http://venturebeat.com/2007/07/30/talecris-biotherapeutics-files-for-1b-ipo-is-it-the-end-of-the-private-equity-boom/#comment-508244 [...] these looks at recent baby steps toward “personalized medicine,” a take on the ridiculously large IPO envisioned by Talecris Biotherapeutics, and two items on startups that aim to pioneer the dawning [...] [...] these looks at recent baby steps toward “personalized medicine,” a take on the ridiculously large IPO envisioned by Talecris Biotherapeutics, and two items on startups that aim to pioneer the dawning [...]

]]> http://venturebeat.com/2007/07/30/talecris-biotherapeutics-files-for-1b-ipo-is-it-the-end-of-the-private-equity-boom/comment-page-1/#comment-401722 VentureBeat » AlphaMed Pharma raising $50M for recombinant alpha-1 antitrypsin Sat, 11 Aug 2007 00:06:44 +0000 http://venturebeat.com/2007/07/30/talecris-biotherapeutics-files-for-1b-ipo-is-it-the-end-of-the-private-equity-boom/#comment-401722 [...] cells. Current forms of the drug, such as one sold by Talecris Biotherapeutics (see our coverage here), are derived from donated blood. Patients who lack the enzyme are prone to emphysema and other [...] [...] cells. Current forms of the drug, such as one sold by Talecris Biotherapeutics (see our coverage here), are derived from donated blood. Patients who lack the enzyme are prone to emphysema and other [...]

]]>